文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

南非耐药结核病患病率及推算负担:一项全国和次国家级横断面调查

Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey.
PubMed 文献 · Lancet Infect Dis · 2018-04-21

该研究于2012年6月15日至2014年6月14日在南非九个省开展横断面调查,采用按人口比例随机整群抽样,共检测101 422名参与者。全国新发结核病例中耐多药结核患病率为2.1%(95%CI 1.5-2.7),复治病例中为4.6%(95%CI 3.2-6.0)。与2001-02年调查相比,耐多药结核总体患病率相似(2.8% vs 2.9%),但新发病例中利福平耐药结核患病率几乎翻倍。

要点

  • 全国新发结核病例耐多药结核患病率为2.1%(95%CI 1.5-2.7)。
  • 复治病例耐多药结核患病率为4.6%(95%CI 3.2-6.0)。
  • 利福平耐药结核总体患病率(4.6%)高于耐多药结核(2.8%),差异有统计学意义(p=0.01)。

核心结论

  • 南非2012-14年耐多药结核总体患病率与2001-02年相似,但新发病例中利福平耐药结核患病率几乎翻倍。
  • 异烟肼单耐药结核患病率高且未被常规筛查,二线药物耐药对经验性治疗有影响。

研究设计与样本

  • 横断面调查,采用按人口比例随机整群抽样,覆盖南非九个省。
  • 共纳入343个群,每省31至48个群。
  • 纳入在耐药调查入组机构就诊的疑似结核患者,参与者≥18岁,完成问卷并留取痰标本检测一线和二线药物耐药。
  • 分析采用逻辑回归(稳健标准误),按常规数据进行逆概率加权,并使用随机效应模型得出估计值。

主要发现

  • 2012-14年共检测101 422名参与者。
  • 全国新发结核病例耐多药结核患病率为2.1%(95%CI 1.5-2.7),复治病例为4.6%(95%CI 3.2-6.0)。
  • 各省耐多药结核点患病率范围为1.6%(95%CI 0.9-2.9)至5.1%(95%CI 3.7-7.0)。
  • 利福平耐药结核总体患病率为4.6%(95%CI 3.5-5.7),高于耐多药结核的2.8%(95%CI 2.0-3.6;p=0.01)。
  • 耐多药结核病例中乙硫异烟胺耐药患病率为44.7%(95%CI 25.9-63.6),吡嗪酰胺耐药为59.1%(95%CI 49.0-69.1);广泛耐药结核患病率为4.9%(95%CI 1.0-8.8)。

关键数值与推荐

  • 与2001-02年调查相比,耐多药结核总体患病率为2.8% vs 2.9%,利福平耐药结核患病率为3.4% vs 1.8%。
  • 异烟肼单耐药结核患病率在所有省份均超过5%。
  • 2014年全国估算利福平耐药结核、耐多药结核和异烟肼单耐药结核病例数分别为13 551例、8249例和17 970例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Globally, per-capita, South Africa reports a disproportionately high number of cases of multidrug-resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis. We sought to estimate the prevalence of resistance to tuberculosis drugs in newly diagnosed and retreated patients with tuberculosis provincially and nationally, and compared these with the 2001-02 estimates. METHODS: A cross-sectional survey was done between June 15, 2012-June 14, 2014, using population proportionate randomised cluster sampling in the nine provinces in South Africa. 343 clusters were included, ranging between 31 and 48 per province. A patient was eligible for inclusion in the survey if he or she presented as a presumptive case during the intake period at a drug resistance survey enrolling facility. Consenting participants (≥18 years old) completed a questionnaire and had a sputum sample tested for resistance to first-line and second-line drugs. Analysis was by logistic regression with robust SEs, inverse probability weighted against routine data, and estimates were derived using a random effects model. FINDINGS: 101 422 participants were tested in 2012-14. Nationally, the prevalence of MDR tuberculosis was 2·1% (95% CI 1·5-2·7) among new tuberculosis cases and 4·6% (3·2-6·0) among retreatment cases. The provincial point prevalence of MDR tuberculosis ranged between 1·6% (95% CI 0·9-2·9) and 5·1% (3·7-7·0). Overall, the prevalence of rifampicin-resistant tuberculosis (4·6%, 95% CI 3·5-5·7) was higher than the prevalence of MDR tuberculosis (2·8%, 2·0-3·6; p=0·01). Comparing the current survey with the previous (2001-02) survey, the overall MDR tuberculosis prevalence was 2·8% versus 2·9% and prevalance of rifampicin-resistant tuberculosis was 3·4% versus 1·8%, respectively. The prevalence of isoniazid mono-resistant tuberculosis was above 5% in all provinces. The prevalence of ethionamide and pyrazinamide resistance among MDR tuberculosis cases was 44·7% (95% CI 25·9-63·6) and 59·1% (49·0-69·1), respectively. The prevalence of XDR tuberculosis was 4·9% (95% CI 1·0-8·8). Nationally, the estimated numbers of cases of rifampicin-resistant tuberculosis, MDR tuberculosis, and isoniazid mono-resistant tuberculosis for 2014 were 13 551, 8249, and 17 970, respectively. INTERPRETATION: The overall prevalence of MDR tuberculosis in South Africa in 2012-14 was similar to that in 2001-02; however, prevalence of rifampicin-resistant tuberculosis almost doubled among new cases. Furthermore, the high prevalence of isoniazid mono-resistant tuberculosis, not routinely screened for, and resistance to second-line drugs has implications for empirical management. FUNDING: President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention under the terms of 1U19GH000571.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ismail NA, Mvusi L, Nanoo A, et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018. PMID: 29685458. doi:10.1016/S1473-3099(18)30222-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。